Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer

Q3 Medicine
Jingran Ji, Jaideep Sandhu, Chongkai Wang, Marwan Fakih
{"title":"Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer","authors":"Jingran Ji,&nbsp;Jaideep Sandhu,&nbsp;Chongkai Wang,&nbsp;Marwan Fakih","doi":"10.1016/j.ctarc.2023.100714","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite recent advancements in the treatment of metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer (CRC), prognosis remains poor. However, a some patients with <em>BRAF<sup>V600E</sup></em> disease have superior outcomes compared to the overall cohort and the prognostic factors associated with this improved survival are not well understood.</p></div><div><h3>Methods</h3><p>We conducted a single center retrospective review of patients with metastatic CRC and available next generation sequencing data. Patients with confirmed <em>BRAF<sup>V600E</sup></em> disease were selected for the final analysis. We collected baseline demographic characteristics, concurrent mutations, and metastatic pattern. The primary endpoint was overall survival (OS). Univariate and multivariable logistic regression was used to examine the association between baseline concurrent somatic mutations and sites of metastatic disease with survival.</p></div><div><h3>Results</h3><p>Of 466 patients with metastatic CRC, 50 harbored <em>BRAF<sup>V600E</sup></em> disease and 42 were included in the final analysis. The median OS in this cohort was 18.7 months (95% CI: 5.55–31.8). There was no association between baseline concurrent somatic mutations and OS. On univariate analysis, patients with lymph node only disease at the time of metastatic disease were more likely to have longer OS (hazard ratio [HR] = 0.30, 95% CI: 0.09–0.98, <em>p</em> = 0.047) and patients with peritoneal disease were more likely to have shorter OS (HR = 2.78, 95% CI: 1.12–6.88, <em>p</em> = 0.03). However, these associations did not retain statistical significance on multivariable analysis.</p></div><div><h3>Conclusions</h3><p>The pattern of metastatic disease in <em>BRAF<sup>V600E</sup></em> CRC may be a prognostic factor and future studies are needed to better understand the underlying mechanisms and potentially change clinical practice for a select patient population.</p></div><div><h3>MicroAbstract</h3><p>Select patients with metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer may have better than expected survival but are not well characterized. We conducted a retrospective review of 42 patients with metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer and showed that lymph node only disease at the time of metastatic disease was associated with superior survival.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Despite recent advancements in the treatment of metastatic BRAFV600E colorectal cancer (CRC), prognosis remains poor. However, a some patients with BRAFV600E disease have superior outcomes compared to the overall cohort and the prognostic factors associated with this improved survival are not well understood.

Methods

We conducted a single center retrospective review of patients with metastatic CRC and available next generation sequencing data. Patients with confirmed BRAFV600E disease were selected for the final analysis. We collected baseline demographic characteristics, concurrent mutations, and metastatic pattern. The primary endpoint was overall survival (OS). Univariate and multivariable logistic regression was used to examine the association between baseline concurrent somatic mutations and sites of metastatic disease with survival.

Results

Of 466 patients with metastatic CRC, 50 harbored BRAFV600E disease and 42 were included in the final analysis. The median OS in this cohort was 18.7 months (95% CI: 5.55–31.8). There was no association between baseline concurrent somatic mutations and OS. On univariate analysis, patients with lymph node only disease at the time of metastatic disease were more likely to have longer OS (hazard ratio [HR] = 0.30, 95% CI: 0.09–0.98, p = 0.047) and patients with peritoneal disease were more likely to have shorter OS (HR = 2.78, 95% CI: 1.12–6.88, p = 0.03). However, these associations did not retain statistical significance on multivariable analysis.

Conclusions

The pattern of metastatic disease in BRAFV600E CRC may be a prognostic factor and future studies are needed to better understand the underlying mechanisms and potentially change clinical practice for a select patient population.

MicroAbstract

Select patients with metastatic BRAFV600E colorectal cancer may have better than expected survival but are not well characterized. We conducted a retrospective review of 42 patients with metastatic BRAFV600E colorectal cancer and showed that lymph node only disease at the time of metastatic disease was associated with superior survival.

转移模式是BRAFV600E突变型癌症的预后因素
背景尽管最近在转移性BRAFV600E癌症(CRC)的治疗方面取得了进展,但预后仍然很差。然而,与整个队列相比,一些BRAFV600E疾病患者的预后更好,与这种生存率提高相关的预后因素尚不清楚。方法我们对转移性CRC患者和可用的下一代测序数据进行了单中心回顾性审查。选择患有BRAFV600E疾病的患者进行最终分析。我们收集了基线人口统计学特征、并发突变和转移模式。主要终点是总生存期(OS)。使用单变量和多变量逻辑回归来检验基线并发体细胞突变和转移性疾病部位与生存率之间的关系。结果466例转移性CRC患者中,50例携带BRAFV600E疾病,42例纳入最终分析。该队列的中位OS为18.7个月(95%CI:5.55–31.8)。基线并发体细胞突变与OS之间没有关联。在单变量分析中,转移性疾病时仅患有淋巴结疾病的患者更有可能有更长的OS(风险比[HR]=0.30,95%CI:0.09–0.98,p=0.047),腹膜疾病患者更有可能更短的OS(HR=2.78,95%CI:1.12–6.88,p=0.03)。然而,这些关联在多变量分析中没有保留统计学意义。结论BRAFV600E CRC的转移性疾病模式可能是一个预后因素,需要未来的研究来更好地了解潜在的机制,并可能改变选定患者群体的临床实践。微摘要选择患有转移性BRAFV600E癌症的患者可能具有比预期更好的生存率,但没有很好的特征。我们对42例转移性BRAFV600E癌症患者进行了回顾性研究,结果表明转移性疾病时仅淋巴结疾病与较高的生存率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信